In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Duke study shows that oral drug may improve survival in men with metastatic prostate cancer
NCI Cancer Center News
- An investigational prostate cancer treatment slows the disease’s progression and may increase survival, especially among men whose cancer has spread to the bones, according an analysis led by the Duke Cancer Institute.

Worldwide trends show oropharyngeal cancer rates increasing
NCI News Note
(Posted: 11/20/2013) - NCI scientists report that the incidence of oropharyngeal cancer significantly increased during the period 1983-2002 among people in countries that are economically developed. Oropharyngeal cancer occurs primarily in the middle part of the throat behind the mouth, including the base of the tongue, the side and back walls of the throat, and the tonsils.

Obesity found to be major risk factor in developing basal-like breast cancer
NCI Cancer Center News
- In a study published online by the journal Breast Cancer Research and Treatment, a team from the UNC Gillings School of Global Public Health and the UNC Lineberger Comprehensive Cancer Center outlined, in a mouse model, the biological mechanisms where obesity can create a favorable environment for the growth of basal-like breast cancer tumors.

Researchers work to improve outcomes of lymphoma patients
NCI Cancer Center News
- Researchers at the University of Nebraska Medical Center (home of the Fred & Pamela Buffett Cancer Center) have discovered that patients with diffuse large B-cell lymphoma don't respond well to the standard drug therapy used to treat this type of cancer if they have high levels of a gene called STAT3. The findings are published in the November issue of the Journal of Clinical Oncology, the medical journal of the American Society for Clinical Oncology.

How a common chemo drug thwarts graft rejection in bone marrow transplants
NCI Cancer Center News
- Results of a study from Johns Hopkins and its Kimmel Cancer Center may explain why a chemotherapy drug called cyclophosphamide prevents graft-versus-host (GVHD) disease in people who receive bone marrow transplants. The experiments point to an immune system cell that evades the toxic effects of cyclophosphamide and protects patients from a lethal form of GVHD. The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.

Deletion of any single gene in yeast provokes mutations elsewhere in the genome
NCI Cancer Center News
- Johns Hopkins researchers report that the deletion of any single gene in yeast cells puts pressure on the organism's genome to compensate, leading to a mutation in another gene. Their discovery, which is likely applicable to human genetics because of the way DNA is conserved across species, could have significant consequences for the way genetic analysis is done in cancer and other areas of research, they say. Johns Hopkins is home to the Kimmel Cancer Center.

Clinical trial finds concurrent therapy not necessary to achieve high pathological remission in breast cancer
NCI Cancer Center News
- Giving trastuzumab and anthracyclines at the same time is effective at treating HER-2-positive breast cancer, but there is concern that this combination can be associated with an increased risk of cardiac toxicity. New research from The University of Texas MD Anderson Cancer Center and colleagues in the Alliance for Clinical Trials in Oncology, shows these agents do not need to be given concurrently to achieve a high rate of complete pathological remission.

Hormonal levels affect endometrial cancer drug efficiency
NCI Cancer Center News
- Modulating the hormonal environment in which endometrial cancers grow could make tumors significantly more sensitive to a new class of drugs known as PARP inhibitors, a researcher at UCLA’s Jonsson Comprehensive Cancer Center has shown for the first time. The findings could lead to a novel one-two punch therapy to fight endometrial cancers and provide an alternative option for conventional treatments that, particularly in advanced disease, have limited efficacy.

NIH study finds low-intensity therapy for Burkitt lymphoma is highly effective
NCI Press Release
(Posted: 11/13/2013) - Adult patients with a type of cancer known as Burkitt lymphoma had excellent long-term survival rates—upwards of 90 percent—following treatment with low-intensity chemotherapy regimens, according to a new clinical trial finding. Burkitt lymphoma is the most aggressive type of lymphoma, which is a cancer that begins in cells of the immune system.

Young breast cancer patients with poorer financial status may experience delays in seeking care
NCI Cancer Center News
(Posted: 11/12/2013) - Researchers who sought to determine why breast cancers are more deadly in young women found that only a minority of young women experience long delays between the time they detect a breast abnormality and the time they receive a diagnosis, but delays in seeking care are more common in women with fewer financial resources. Findings of the study, conducted at the Dana-Farber Cancer Institute in Boston, are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.

< Previous  8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28  Next >